- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Editas Medicine Inc (EDIT)
Editas Medicine Inc stock price live, this page displays NASDAQ EDIT stock exchange data. View the EDIT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Editas Medicine Inc real time stock price chart below.
What Is the Editas Medicine Inc Stock Price Today?
The Editas Medicine Inc stock price today is 2.76.
What Is the Stock Symbol for Editas Medicine Inc?
The stock symbol for Editas Medicine Inc is "EDIT."
What Stock Exchange Does Editas Medicine Inc Trade On?
Editas Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Editas Medicine Inc a Good Stock to Buy?
Determining whether Editas Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EDIT quote. (ISIN: US28106W1036)
What Is the Editas Medicine Inc Stock Price Today?
The Editas Medicine Inc stock price today is 2.76.
What Is the Stock Symbol for Editas Medicine Inc?
The stock symbol for Editas Medicine Inc is "EDIT."
What Stock Exchange Does Editas Medicine Inc Trade On?
Editas Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Editas Medicine Inc a Good Stock to Buy?
Determining whether Editas Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the EDIT quote. (ISIN: US28106W1036)
Currency in USD
2.76
+0.03(+1.10%)
Closed·
After Hours
2.73-0.03(-1.09%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.66
2.87
52 wk Range
0.91
5.85
EDIT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 10 days
More Info
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.662.87
52 wk Range
0.915.85
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EDIT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Neutral
Price Target
3.38
Upside
+22.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
4 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Editas Medicine Company Profile
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine Inc SWOT Analysis
Strategic Pivot | Explore Editas Medicine's shift to in vivo gene editing, streamlining operations and extending financial runway amid program discontinuations and workforce reductions |
Financial Outlook | Analyst projections show EPS of -$1.42 for FY2025, with cash runway extended to Q2 2027. Price targets range from $3 to $8, averaging around $5 |
Competitive Edge | Delve into Editas' unique focus on up-regulation techniques in gene editing, differentiating itself in a crowded market of genetic disorder treatments |
IP Portfolio Powe | Learn how Editas' robust patent estate could drive value through strategic partnerships and licensing deals, potentially opening new revenue streams |
Compare EDIT to Peers and Sector
Metrics to compare | EDIT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEDITPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −1.7x | −0.5x | |
PEG Ratio | 0.02 | −0.07 | 0.00 | |
Price/Book | 3.7x | 1.5x | 2.6x | |
Price / LTM Sales | 6.4x | 14.0x | 3.2x | |
Upside (Analyst Target) | 26.8% | 217.8% | 44.3% | |
Fair Value Upside | Unlock | 20.8% | 6.6% | Unlock |
Analyst Ratings
5 Buy
8 Hold
2 Sell
Ratings:
15 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 3.38
(+22.28% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.92 / -0.56
Revenue / Forecast
4.66M / 786.10K
FAQ
What Is the Editas Medicine (EDIT) Stock Price Today?
The Editas Medicine stock price today is 2.76.
What Stock Exchange Does Editas Medicine Trade On?
Editas Medicine is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Editas Medicine?
The stock symbol for Editas Medicine is "EDIT."
What Is the Editas Medicine Market Cap?
As of today, Editas Medicine market cap is 231.05M.
What Is Editas Medicine's Earnings Per Share (TTM)?
The Editas Medicine EPS (TTM) is -3.04.
When Is the Next Editas Medicine Earnings Date?
Editas Medicine will release its next earnings report on 29 Jul 2025.
From a Technical Analysis Perspective, Is EDIT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Editas Medicine Stock Split?
Editas Medicine has split 0 times.
How Many Employees Does Editas Medicine Have?
Editas Medicine has 246 employees.
What is the current trading status of Editas Medicine (EDIT)?
As of 20 Jul 2025, Editas Medicine (EDIT) is trading at a price of 2.76, with a previous close of 2.73. The stock has fluctuated within a day range of 2.66 to 2.87, while its 52-week range spans from 0.91 to 5.85.
What Is Editas Medicine (EDIT) Price Target According to Analysts?
The average 12-month price target for Editas Medicine is USD3.375, with a high estimate of USD5 and a low estimate of USD1. 5 analysts recommend buying the stock, while 2 suggest selling, leading to an overall rating of Neutral. The stock has an +22.28% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.